Page last updated: 2024-09-04

tezosentan and Liver Cirrhosis

tezosentan has been researched along with Liver Cirrhosis in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dingemanse, J; Halabi, A; van Giersbergen, PL	1
Baumelou, A; Izzedine, H	1
Bosch, J; Chiossi, E; Dingemanse, J; Dudley, FJ; Garcia-Pagan, JC; Jalan, R; Jessic, R; Kusic-Pajic, A; Lebrec, D; Mookerjee, RP; Moreau, R; Van Giersbergen, PL	1
Barriere, E; Cazals-Hatem, D; Guimont, MC; Lebrec, D; Martin, A; Moreau, R; Poirel, O; Sogni, P; Tazi, KA; Urbanowicz, W	1
Dingemanse, J; Jalan, R; Moore, K; Wong, F	1

Trials

3 trial(s) available for tezosentan and Liver Cirrhosis

Article	Year
Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. Journal of clinical pharmacology, 2009, Volume: 49, Issue:4 Topics: Adult; Bilirubin; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin-1; Female; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Placebos; Pyridines; Tetrazoles; Vasodilator Agents	2009
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. European journal of clinical pharmacology, 2012, Volume: 68, Issue:5 Topics: Antihypertensive Agents; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Female; Heart Rate; Hemodynamics; Humans; Hypertension, Portal; Infusions, Parenteral; Liver; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Metabolic Clearance Rate; Middle Aged; Pyridines; Severity of Illness Index; Splanchnic Circulation; Tetrazoles; Vasodilator Agents	2012
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology (Baltimore, Md.), 2008, Volume: 47, Issue:1 Topics: Endothelin-1; Hemodynamics; Hepatorenal Syndrome; Humans; Kidney; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyridines; Sodium; Tetrazoles; Treatment Failure; Water	2008

Other Studies

2 other study(ies) available for tezosentan and Liver Cirrhosis

Article	Year
Renal failure in cirrhosis. The New England journal of medicine, 2010, Jan-07, Volume: 362, Issue:1 Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Pyridines; Renal Insufficiency; Sulfonamides; Tetrazoles	2010
Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut, 2004, Volume: 53, Issue:12 Topics: Animals; Endothelin Receptor Antagonists; Endothelins; Endotoxemia; Lipopolysaccharides; Liver; Liver Cirrhosis; Male; Neutrophil Infiltration; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Tetrazoles; Transaminases; Tumor Necrosis Factor-alpha; Vasodilator Agents	2004

Article

Year

Renal failure in cirrhosis.

The New England journal of medicine, 2010, Jan-07, Volume: 362, Issue:1

Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Pyridines; Renal Insufficiency; Sulfonamides; Tetrazoles

2010

Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.

Gut, 2004, Volume: 53, Issue:12

Topics: Animals; Endothelin Receptor Antagonists; Endothelins; Endotoxemia; Lipopolysaccharides; Liver; Liver Cirrhosis; Male; Neutrophil Infiltration; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Tetrazoles; Transaminases; Tumor Necrosis Factor-alpha; Vasodilator Agents

2004